Athersys is a biotechnology company, focused on the field of regenerative medicine. Co.'s MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its primary platform product and is in late-stage clinical development. Co.'s existing clinical development programs are focused on treating neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease and other conditions where the existing standard of care is limited or inadequate for several patients. Co.'s product development programs include ischemic stroke, which is in a Phase 3 clinical trial for the treatment of ischemic stroke, referred to as MASTERS-2. The ATHX stock yearly return is shown above.
The yearly return on the ATHX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ATHX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|